TelyRx Holdings Inc. is seeing a notable rise in its stock price, reflecting positive market sentiment.
Today, TelyRx Holdings Inc. (TELY.TO) shares are up 2.13% to CA$2.40. This increase comes as interest grows in the company's digital pharmacy services, which have recently surpassed one million prescriptions filled nationwide.
Advertisement
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$62.49M
52W high
$4.25
52W low
$2.00
1W change
-4.00%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 150.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+150.0% Upside
Current Price
C$2.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
99.8%
Annualized
90-Day Vol
95.3%
Annualized
Trend (90d)
+17.9%
Annualized drift
90d Mean
C$2.56
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.45 | C$1.74 โ C$3.46 |
| 60 trading days | C$2.50 | C$1.54 โ C$4.08 |
| 90 trading days | C$2.56 | C$1.41 โ C$4.65 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors might interpret TelyRx's stock increase as a sign of growing market confidence, especially as the company continues to report significant revenue growth.
TelyRx's Market Cap Reaches CA$63.8 Million
With a market cap of CA$63.8 million, TelyRx is navigating a competitive sector, but its recent revenue growth shows a promising trajectory.
Bull case
TelyRx's recent performance indicates strong demand for its services. This demand could lead to sustained revenue growth and potential profitability in the future.
Bear case
Despite today's gains, TelyRx is still operating at a loss. Any downturn in market sentiment or operational challenges could negatively impact its stock price.
Strong Revenue Growth
Advertisement
TelyRx recently reported a significant revenue increase, jumping to CA$42.9 million for the year ending December 31, 2025, compared to CA$9.5 million in 2024. This growth reflects rising demand for their services and could boost investor confidence. For more details, check out the year-end financial results.
Market Performance Insights
The current rise in TelyRx's stock price aligns with broader market trends favoring companies in the digital health sector. Investors are increasingly interested in innovative healthcare solutions, and TelyRx's recent milestones, like surpassing one million prescriptions, highlight its growth potential. For insights into their recent performance, visit TelyRx's stock page.
Future Outlook
While TelyRx's stock is performing well today, investors should stay cautious. The company is still operating at a loss, and any future challenges in scaling its services could impact its market position. Keeping an eye on upcoming financial reports will be crucial for assessing its long-term viability. For ongoing updates, follow our coverage on TelyRx Holdings.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
